Dow Jones
39.112,16 -299,05 (-0,76%) Nasdaq
17.717,65 +220,84 (+1,26%) Nikkei 225
39.672,40 +499,25 (+1,27%) EUR/USD
1,0714 -0,0002 (-0,02%) Bitcoin EUR
57.664,87 +491,28 (+0,86%) CMC Crypto 200
1.280,53 +31,41 (+2,51%)
IOVA Jan 2025 12.500 put
| Chiusura precedente | 5,33 |
| Aperto | 5,33 |
| Denaro | 4,80 |
| Domanda | 5,00 |
| Prezzo d'esercizio | 12,50 |
| Scadenza | 2025-01-17 |
| Min-Max giorno | 5,33 - 5,33 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 789 |
GlobeNewswireIovance Biotherapeutics Announces Clinical Data for Lifileucel in Advanced Mucosal Melanoma at the European Society for Medical Oncology (ESMO) Congress
SAN CARLOS, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the publication of an abstract reporting clinical data for lifileucel which will be presented at the European Society for Medical Oncology ESMO Congress 2023, October 20-24, 2023 in Madrid, Spain. The abstract reports out
- GlobeNewswire
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Four-year Analysis of C-144-01 Trial Cohorts 2 and 4SAN CARLOS, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte (TIL) therapies at the Society for Immunotherapy of Cancer’s (SITC) 38th
- GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on September 21, 2023 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 174,400 shares of Iovance’s common stock to eleven new non-executive employees. The aw
